On June 11, 2018, we had our first FaceShield™ prototype tested for Bacterial Filtration Efficiency (BFE) using a reputable, independent international laboratory. The labs test method was designed to challenge the FaceShield under normal use circumstances. The challenge organism used in this test was Staphylococcus Aureus. The result was that the FaceShield™ could filter 86.3% of bacteria.
On November 19, 2018, we had the FaceShield™ re-tested for bacterial filtration efficiency. This time according to the international standard test method ASTM-F2101 where a liquid suspension of Staphylococcus Aureus is aerosolized and delivered to the filtration media at a constant flow rate of 28.3 litres per minute (LPM) or 1 cubic foot per minute (CFM). This test standard was developed for testing the effectiveness of disposable surgical masks. As an average adult will expel 28.3 litres of air per minute, it aims to mimic the pressures that a surgical mask would undergo in the real world application. Our result with this standard of testing was 40%.
On July 29, 2020, the FaceShield™ was also tested for Viral Filtration Efficiency (VFE). The VFE test follows the same procedure as ASTM-F2101, except the challenge organism used is the bacteriophage phiX174 which is controlled to ensure a mean particle size of 3.0 ± 0.3 µm. Our results showed that the FaceShield™ could filter 43% of the challenge virus.
Under normal use conditions, the FaceShield™ would undergo pressures closer to that of our first test method due to the design of the face opening allowing the expelled air to exit easily. Our patented design has the ability to provide this bacterial filtration in both directions – from the customer to the therapy bed and vice versa.🡠 Back to Swabs Testing View Clinical Testing 🡢
WORLD'S FIRST RESEARCH ― A significant amount of government funding is consistently allocated to research into infection risks and prevention in hospital environments, however, the same can't be said for therapy environments. This lack of research prompted us to commission our own preliminary research into the infection risks associated with therapy beds, with a focus on the transmission of both bacteria and saliva. The results are in and they will shock you!